Life Biosciences Conducts First Gene Therapy Trial to Reverse Cellular Aging in Patient with Glaucoma
By
Darren Orf
Summary
Life Biosciences, a Boston-based biotech startup, has conducted the world's first gene therapy on a living patient aimed at reversing cellular aging. The Phase 1 clinical trial targets open-angle glaucoma (OAG), the most common form of optic neuropathy that causes vision loss. The therapy is designed to reprogram old cells to behave young again, potentially treating incurable vision loss, though the approach carries risks including cancer.
Source
Twitter / XLife Biosciences Conducts First Gene Therapy Trial to Reverse Cellular Aging in Patient with Glaucomapopularmechanics.comKey quotes
· 3 pulledOn June 9, Life Biosciences—a Boston-based biotech startup—conducted the world's first gene therapy designed to treat optic neuropathies on a living patient.
As we age, so do our cells. But some scientists are wondering if we actually need to accept this inevitable entropy.
The treatment specifically targets open-angle glaucoma (OAG), the most common form of the disease, which clogs the drainage system of the eye and damages the optic nerve.
You might also wanna read
Life Biosciences Doses First Patient in FDA-Approved Gene Therapy Trial for Age-Related Blindness
Life Biosciences has dosed its first patient in an FDA-approved clinical trial testing a gene therapy designed to reverse cellular aging. Th
gizmodo.com·16d ago
Life Biosciences Begins First Human Trial of Cellular Rejuvenation Drug for Age-Related Vision Loss
Life Biosciences has dosed the first human patient with ER-100, a cellular rejuvenation therapy designed to reverse age-related sight loss b
wired.com·11d ago
Life Biosciences' ER-100 gene therapy aims to restore vision by rejuvenating retinal neurons through epigenetic reprogramming
Life Biosciences has developed ER-100, a first-ever experimental gene therapy that aims to restore vision by rejuvenating damaged retinal ne
interestingengineering.com·19d ago
First human treated in gene therapy trial aiming to reverse cellular aging through partial reprogramming
A landmark clinical trial has begun treating the first human participant with a gene therapy that aims to reverse cellular aging. The approa
scientificamerican.com·12d ago
First human trial of cellular aging reversal therapy approved for January 2026 using Yamanaka factor molecular switches
The article reports on the first human trial approved in January 2026 for a therapy designed to partially reverse cellular aging using Yaman
spacedaily.com·10d ago
Researchers Develop Experimental 'Living Eye Drops' Using Engineered Bacteria to Heal Corneas
Researchers are developing experimental "living eye drops" that use genetically engineered bacteria to heal the cornea. The therapy, created
bit.ly·10d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.